<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02761213</url>
  </required_header>
  <id_info>
    <org_study_id>KC16MISV0004</org_study_id>
    <nct_id>NCT02761213</nct_id>
  </id_info>
  <brief_title>Oral Sulfate Solution (SUPREP) Versus Polyethylene Glycol (PEG) Plus Ascorbic Acid</brief_title>
  <official_title>Efficacy of Reduced Volume Oral Sulfate Solution (SUPREP) Compared With PEG Plus Ascorbic Acid for Screening Colonoscopy: Single Center, Single Blinded Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bo-In Lee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmbio Korea Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of the present study is to compare oral sulfate solution (OSS) with low-dose
      polyethylene glycol plus ascorbic acid (2-L PEG/Asc) for bowel cleansing efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High-quality bowel cleansing is critical to effective colonoscopy. Studies in the past decade
      have demonstrated that many clinical practices continue to have rates of adequate preparation
      as low as 60% to 80%.

      Low-volume preparations for colonoscopy are designed to improve patient tolerability, another
      important aspect of bowel preparation. In addition, low-volume preparations should ideally
      not sacrifice efficacy. There are few data comparing the efficacy of available low-volume
      bowel preparations.

      In this study, we describe a prospective, single-blind, randomized, controlled trial
      comparing oral sulfate solution (OSS) (SUPREP, Braintree Laboratories, Braintree, Mass) with
      low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Boston Bowel Preparation Scale (BPPS)</measure>
    <time_frame>during colonoscopy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Aronchick scale</measure>
    <time_frame>during colonoscopy</time_frame>
    <description>Aronchick scale is a commonly used bowel preparation scale to grade the adequacy of cleansing of colonic segments or the entire colon.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability by a patient questionnaire using 5-point Likert scale</measure>
    <time_frame>on arrival at the endoscopy unit before colonoscopy</time_frame>
    <description>to assess tolerability of each bowel preparation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety by measuring hemodynamic and biochemical data</measure>
    <time_frame>at baseline (in the clinic be- fore booking the colonoscopy) and on arrival at the en- doscopy suite</time_frame>
    <description>Biochemical data will be measured only in case of necessity such as weakness, mental change or numbness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonoscopic finding: whether there is erythematous mucosal change or apthous ulcers</measure>
    <time_frame>during colonoscopy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of cecal intubation</measure>
    <time_frame>during colonoscopy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insertion time</measure>
    <time_frame>during colonoscopy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal time</measure>
    <time_frame>during colonoscopy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adenoma detection rate</measure>
    <time_frame>during colonoscopy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Cathartic Colon</condition>
  <arm_group>
    <arm_group_label>Oral sulfate solution (OSS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral sulfate solution (OSS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-L PEG/Asc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral sulfate solution (OSS)</intervention_name>
    <description>Oral sulfate solution (OSS)</description>
    <arm_group_label>Oral sulfate solution (OSS)</arm_group_label>
    <other_name>SUPREP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2-L PEG/Asc</intervention_name>
    <description>Low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc) COOLPREP is a proprietary name of 2-L PEG/Asc.</description>
    <arm_group_label>2-L PEG/Asc</arm_group_label>
    <other_name>COOLPREP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  people who receive colonoscopy

          -  aged : 18-80

          -  people who sign the consent

        Exclusion Criteria:

          -  those aged over 80 years

          -  the disabled

          -  intestinal obstruction

          -  severe constipation

          -  previous history of bowel resection

          -  liver cirrhosis

          -  heart failure or ischemic heart disease within 6 months

          -  inflammatory bowel disease

          -  pregnant women

          -  severe renal insufficiency

          -  people who refuse to sign the consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo-In Lee, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-040</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Rex DK, Petrini JL, Baron TH, Chak A, Cohen J, Deal SE, Hoffman B, Jacobson BC, Mergener K, Petersen BT, Safdi MA, Faigel DO, Pike IM; ASGE/ACG Taskforce on Quality in Endoscopy. Quality indicators for colonoscopy. Am J Gastroenterol. 2006 Apr;101(4):873-85.</citation>
    <PMID>16635231</PMID>
  </reference>
  <reference>
    <citation>Bannas P, Bakke J, Patrick JL, Pickhardt PJ. Automated volumetric analysis for comparison of oral sulfate solution (SUPREP) with established cathartic agents at CT colonography. Abdom Imaging. 2015 Jan;40(1):11-8. doi: 10.1007/s00261-014-0186-x. Erratum in: Abdom Imaging. 2015 Aug;40(6):2066.</citation>
    <PMID>24965898</PMID>
  </reference>
  <reference>
    <citation>Rex DK, DiPalma JA, McGowan J, Cleveland Mv. A comparison of oral sulfate solution with sodium picosulfate: magnesium citrate in split doses as bowel preparation for colonoscopy. Gastrointest Endosc. 2014 Dec;80(6):1113-23. doi: 10.1016/j.gie.2014.05.329. Epub 2014 Jul 12.</citation>
    <PMID>25028274</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2016</study_first_submitted>
  <study_first_submitted_qc>May 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Bo-In Lee</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

